Pfizer (PFE) Gets An Opening In ATTR CM After AstraZeneca Trial Failure
View original at finance.yahoo.comPfizer (PFE) Gets An Opening In ATTR CM After AstraZeneca Trial Failure Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Simply Wall St has flagged 4 risks for Pfizer that could impact investment.
60% confidenceThis news supports the narrative that Pfizer's late-stage rare-disease portfolio can contribute to long-term resilience by reducing near-term competitive pressure around ATTR-CM.
60% confidenceThe news challenges the idea that Pfizer must rely heavily on additional partnerships or acquisitions to offset every patent expiry, since an existing franchise appears to have gained relative strength without new deal-making.
60% confidenceAstraZeneca's phase III setback gives Pfizer fresh room to defend and possibly extend its ATTR-CM heart disease position without spending on a new deal.
60% confidenceAstraZeneca reported a phase III failure for its ATTR-CM drug Wainua, shifting attention to competitors in this rare heart disease segment.
60% confidence